Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00518822 | Endometrium | AEH | mitochondrial depolarization | 8/2100 | 23/18723 | 2.57e-03 | 1.89e-02 | 8 |
GO:19043759 | Endometrium | AEH | regulation of protein localization to cell periphery | 25/2100 | 125/18723 | 2.84e-03 | 2.04e-02 | 25 |
GO:00309689 | Endometrium | AEH | endoplasmic reticulum unfolded protein response | 17/2100 | 74/18723 | 2.92e-03 | 2.08e-02 | 17 |
GO:00434914 | Endometrium | AEH | protein kinase B signaling | 37/2100 | 211/18723 | 3.89e-03 | 2.64e-02 | 37 |
GO:00513022 | Endometrium | AEH | regulation of cell division | 32/2100 | 177/18723 | 4.33e-03 | 2.86e-02 | 32 |
GO:1904181 | Endometrium | AEH | positive regulation of membrane depolarization | 5/2100 | 11/18723 | 4.56e-03 | 2.95e-02 | 5 |
GO:003367310 | Endometrium | AEH | negative regulation of kinase activity | 40/2100 | 237/18723 | 5.47e-03 | 3.38e-02 | 40 |
GO:00703015 | Endometrium | AEH | cellular response to hydrogen peroxide | 20/2100 | 98/18723 | 5.64e-03 | 3.46e-02 | 20 |
GO:190288210 | Endometrium | AEH | regulation of response to oxidative stress | 20/2100 | 98/18723 | 5.64e-03 | 3.46e-02 | 20 |
GO:190121416 | Endometrium | AEH | regulation of neuron death | 51/2100 | 319/18723 | 5.82e-03 | 3.55e-02 | 51 |
GO:00064149 | Endometrium | AEH | translational elongation | 13/2100 | 55/18723 | 6.76e-03 | 3.94e-02 | 13 |
GO:00181058 | Endometrium | AEH | peptidyl-serine phosphorylation | 50/2100 | 315/18723 | 7.20e-03 | 4.13e-02 | 50 |
GO:000646915 | Endometrium | AEH | negative regulation of protein kinase activity | 36/2100 | 212/18723 | 7.35e-03 | 4.18e-02 | 36 |
GO:007099716 | Endometrium | AEH | neuron death | 56/2100 | 361/18723 | 7.51e-03 | 4.26e-02 | 56 |
GO:00320917 | Endometrium | AEH | negative regulation of protein binding | 19/2100 | 94/18723 | 7.63e-03 | 4.31e-02 | 19 |
GO:004217617 | Endometrium | EEC | regulation of protein catabolic process | 103/2168 | 391/18723 | 3.54e-16 | 1.52e-13 | 103 |
GO:009719317 | Endometrium | EEC | intrinsic apoptotic signaling pathway | 80/2168 | 288/18723 | 3.35e-14 | 9.13e-12 | 80 |
GO:200123317 | Endometrium | EEC | regulation of apoptotic signaling pathway | 91/2168 | 356/18723 | 1.31e-13 | 3.28e-11 | 91 |
GO:190336217 | Endometrium | EEC | regulation of cellular protein catabolic process | 72/2168 | 255/18723 | 2.66e-13 | 6.13e-11 | 72 |
GO:001049817 | Endometrium | EEC | proteasomal protein catabolic process | 112/2168 | 490/18723 | 6.99e-13 | 1.40e-10 | 112 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RACK1 | SNV | Missense_Mutation | | c.260N>G | p.Leu87Arg | p.L87R | P63244 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0SW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
RACK1 | SNV | Missense_Mutation | novel | c.923N>C | p.Arg308Pro | p.R308P | P63244 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
RACK1 | SNV | Missense_Mutation | | c.357N>T | p.Gln119His | p.Q119H | P63244 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RACK1 | SNV | Missense_Mutation | rs745953408 | c.53N>G | p.Val18Gly | p.V18G | P63244 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RACK1 | SNV | Missense_Mutation | novel | c.32N>C | p.Leu11Pro | p.L11P | P63244 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD |
RACK1 | SNV | Missense_Mutation | rs745953408 | c.53N>G | p.Val18Gly | p.V18G | P63244 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A1IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
RACK1 | insertion | Frame_Shift_Ins | novel | c.819_820insCTTAATTCAAAACTAATTTATTCCTCAGGTCAAAAGTTTTGGGGTGG | p.Val274LeufsTer55 | p.V274Lfs*55 | P63244 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
RACK1 | insertion | Nonsense_Mutation | novel | c.799_800insGAGCCTTATCACCAGCTGTTTCTTCCTCAAGGAATACATAACCAC | p.Val267delinsGlyAlaLeuSerProAlaValSerSerSerArgAsnThrTerProLeu | p.V267delinsGALSPAVSSSRNT*PL | P63244 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
RACK1 | deletion | Frame_Shift_Del | novel | c.334delN | p.Ala112ProfsTer73 | p.A112Pfs*73 | P63244 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
RACK1 | SNV | Missense_Mutation | novel | c.262N>T | p.Arg88Cys | p.R88C | P63244 | protein_coding | deleterious(0.02) | benign(0.071) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |